Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines

Domenico Mastrangelo, Lauretta Massai, Francesco Lo Coco, Nélida Inés Noguera, Loredana Borgia, Giuseppe Fioritoni, Anna Berardi, Antonio Iacone, Michela Muscettola, Elvira Pelosi, Germana Castelli, Ugo Testa, Francesco Di Pisa, Giovanni Grasso

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effect of high doses of intravenous (sodium) ascorbate (ASC) in the treatment of cancer has been controversial although there is growing evidence that ASC in high (pharmacologic) concentrations induces dose-dependent pro-apoptotic death of tumor cells, in vitro. Very few data are available on the role of ASC in the treatment of acute myeloid leukemia (AML). Ascorbate behaves as an antioxidant at low (physiologic), and as pro-oxidant at pharmacologic, concentrations, and this may account for the differences reported in different experimental settings, when human myeloid cell lines, such as HL60, were treated with ASC. Considering the myeloid origin of HL60 cells, and previous literature reports showing that some cell lines belonging to the myeloid lineage could be sensitive to the pro-apoptotic effects of high concentrations of ASC, we investigated in more details the effects of high doses (0.5 to 7 mM) of ASC in vitro, on a variety of human myeloid cell lines including the following: HL60, U937, NB4, NB4-R4 (retinoic acid [RA]-resistant), NB4/AsR (ATO-resistant) acute promyelocytic leukemia (APL)-derived cell lines, and K562 as well as on normal CD34+ progenitors derived from human cord blood. Our results indicate that all analyzed cell lines including all-trans retinoic acid (ATRA)- and arsenic trioxide (ATO)-resistant ones are highly sensitive to the cytotoxic, pro-oxidant effects of high doses of ASC, with an average 50 % lethal concentration (LC50) of 3 mM, depending on cell type, ASC concentration, and time of exposure. Conversely, high doses of ASC neither did exert significant cytotoxic effects nor impaired the differentiation potential in cord blood (CB) CD34+ normal cells. Since plasma ASC concentrations within the millimolar (mM) range can be easily and safely reached by intravenous administration, we conclude that phase I/II clinical trials using high doses of ASC should be designed for patients with advanced/refractory AML and APL.

Original languageEnglish
Pages (from-to)1807-1816
Number of pages10
JournalAnnals of Hematology
Volume94
Issue number11
DOIs
Publication statusPublished - Aug 12 2015

Fingerprint

Myeloid Cells
Ascorbic Acid
Cell Line
Acute Promyelocytic Leukemia
Tretinoin
Fetal Blood
Acute Myeloid Leukemia
Reactive Oxygen Species
Phase II Clinical Trials
Clinical Trials, Phase I
HL-60 Cells
Intravenous Administration
Neoplasms
Cell Death
Antioxidants
In Vitro Techniques
arsenic trioxide

Keywords

  • Ascorbic acid
  • Oxidative stress
  • Reactive oxygen species
  • Redox chemotherapy
  • Sodium ascorbate
  • Vitamin C

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines. / Mastrangelo, Domenico; Massai, Lauretta; Lo Coco, Francesco; Noguera, Nélida Inés; Borgia, Loredana; Fioritoni, Giuseppe; Berardi, Anna; Iacone, Antonio; Muscettola, Michela; Pelosi, Elvira; Castelli, Germana; Testa, Ugo; Di Pisa, Francesco; Grasso, Giovanni.

In: Annals of Hematology, Vol. 94, No. 11, 12.08.2015, p. 1807-1816.

Research output: Contribution to journalArticle

Mastrangelo, D, Massai, L, Lo Coco, F, Noguera, NI, Borgia, L, Fioritoni, G, Berardi, A, Iacone, A, Muscettola, M, Pelosi, E, Castelli, G, Testa, U, Di Pisa, F & Grasso, G 2015, 'Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines', Annals of Hematology, vol. 94, no. 11, pp. 1807-1816. https://doi.org/10.1007/s00277-015-2464-2
Mastrangelo, Domenico ; Massai, Lauretta ; Lo Coco, Francesco ; Noguera, Nélida Inés ; Borgia, Loredana ; Fioritoni, Giuseppe ; Berardi, Anna ; Iacone, Antonio ; Muscettola, Michela ; Pelosi, Elvira ; Castelli, Germana ; Testa, Ugo ; Di Pisa, Francesco ; Grasso, Giovanni. / Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines. In: Annals of Hematology. 2015 ; Vol. 94, No. 11. pp. 1807-1816.
@article{a00a0d62986045639d8c5665d8d07b43,
title = "Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines",
abstract = "The effect of high doses of intravenous (sodium) ascorbate (ASC) in the treatment of cancer has been controversial although there is growing evidence that ASC in high (pharmacologic) concentrations induces dose-dependent pro-apoptotic death of tumor cells, in vitro. Very few data are available on the role of ASC in the treatment of acute myeloid leukemia (AML). Ascorbate behaves as an antioxidant at low (physiologic), and as pro-oxidant at pharmacologic, concentrations, and this may account for the differences reported in different experimental settings, when human myeloid cell lines, such as HL60, were treated with ASC. Considering the myeloid origin of HL60 cells, and previous literature reports showing that some cell lines belonging to the myeloid lineage could be sensitive to the pro-apoptotic effects of high concentrations of ASC, we investigated in more details the effects of high doses (0.5 to 7 mM) of ASC in vitro, on a variety of human myeloid cell lines including the following: HL60, U937, NB4, NB4-R4 (retinoic acid [RA]-resistant), NB4/AsR (ATO-resistant) acute promyelocytic leukemia (APL)-derived cell lines, and K562 as well as on normal CD34+ progenitors derived from human cord blood. Our results indicate that all analyzed cell lines including all-trans retinoic acid (ATRA)- and arsenic trioxide (ATO)-resistant ones are highly sensitive to the cytotoxic, pro-oxidant effects of high doses of ASC, with an average 50 {\%} lethal concentration (LC50) of 3 mM, depending on cell type, ASC concentration, and time of exposure. Conversely, high doses of ASC neither did exert significant cytotoxic effects nor impaired the differentiation potential in cord blood (CB) CD34+ normal cells. Since plasma ASC concentrations within the millimolar (mM) range can be easily and safely reached by intravenous administration, we conclude that phase I/II clinical trials using high doses of ASC should be designed for patients with advanced/refractory AML and APL.",
keywords = "Ascorbic acid, Oxidative stress, Reactive oxygen species, Redox chemotherapy, Sodium ascorbate, Vitamin C",
author = "Domenico Mastrangelo and Lauretta Massai and {Lo Coco}, Francesco and Noguera, {N{\'e}lida In{\'e}s} and Loredana Borgia and Giuseppe Fioritoni and Anna Berardi and Antonio Iacone and Michela Muscettola and Elvira Pelosi and Germana Castelli and Ugo Testa and {Di Pisa}, Francesco and Giovanni Grasso",
year = "2015",
month = "8",
day = "12",
doi = "10.1007/s00277-015-2464-2",
language = "English",
volume = "94",
pages = "1807--1816",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines

AU - Mastrangelo, Domenico

AU - Massai, Lauretta

AU - Lo Coco, Francesco

AU - Noguera, Nélida Inés

AU - Borgia, Loredana

AU - Fioritoni, Giuseppe

AU - Berardi, Anna

AU - Iacone, Antonio

AU - Muscettola, Michela

AU - Pelosi, Elvira

AU - Castelli, Germana

AU - Testa, Ugo

AU - Di Pisa, Francesco

AU - Grasso, Giovanni

PY - 2015/8/12

Y1 - 2015/8/12

N2 - The effect of high doses of intravenous (sodium) ascorbate (ASC) in the treatment of cancer has been controversial although there is growing evidence that ASC in high (pharmacologic) concentrations induces dose-dependent pro-apoptotic death of tumor cells, in vitro. Very few data are available on the role of ASC in the treatment of acute myeloid leukemia (AML). Ascorbate behaves as an antioxidant at low (physiologic), and as pro-oxidant at pharmacologic, concentrations, and this may account for the differences reported in different experimental settings, when human myeloid cell lines, such as HL60, were treated with ASC. Considering the myeloid origin of HL60 cells, and previous literature reports showing that some cell lines belonging to the myeloid lineage could be sensitive to the pro-apoptotic effects of high concentrations of ASC, we investigated in more details the effects of high doses (0.5 to 7 mM) of ASC in vitro, on a variety of human myeloid cell lines including the following: HL60, U937, NB4, NB4-R4 (retinoic acid [RA]-resistant), NB4/AsR (ATO-resistant) acute promyelocytic leukemia (APL)-derived cell lines, and K562 as well as on normal CD34+ progenitors derived from human cord blood. Our results indicate that all analyzed cell lines including all-trans retinoic acid (ATRA)- and arsenic trioxide (ATO)-resistant ones are highly sensitive to the cytotoxic, pro-oxidant effects of high doses of ASC, with an average 50 % lethal concentration (LC50) of 3 mM, depending on cell type, ASC concentration, and time of exposure. Conversely, high doses of ASC neither did exert significant cytotoxic effects nor impaired the differentiation potential in cord blood (CB) CD34+ normal cells. Since plasma ASC concentrations within the millimolar (mM) range can be easily and safely reached by intravenous administration, we conclude that phase I/II clinical trials using high doses of ASC should be designed for patients with advanced/refractory AML and APL.

AB - The effect of high doses of intravenous (sodium) ascorbate (ASC) in the treatment of cancer has been controversial although there is growing evidence that ASC in high (pharmacologic) concentrations induces dose-dependent pro-apoptotic death of tumor cells, in vitro. Very few data are available on the role of ASC in the treatment of acute myeloid leukemia (AML). Ascorbate behaves as an antioxidant at low (physiologic), and as pro-oxidant at pharmacologic, concentrations, and this may account for the differences reported in different experimental settings, when human myeloid cell lines, such as HL60, were treated with ASC. Considering the myeloid origin of HL60 cells, and previous literature reports showing that some cell lines belonging to the myeloid lineage could be sensitive to the pro-apoptotic effects of high concentrations of ASC, we investigated in more details the effects of high doses (0.5 to 7 mM) of ASC in vitro, on a variety of human myeloid cell lines including the following: HL60, U937, NB4, NB4-R4 (retinoic acid [RA]-resistant), NB4/AsR (ATO-resistant) acute promyelocytic leukemia (APL)-derived cell lines, and K562 as well as on normal CD34+ progenitors derived from human cord blood. Our results indicate that all analyzed cell lines including all-trans retinoic acid (ATRA)- and arsenic trioxide (ATO)-resistant ones are highly sensitive to the cytotoxic, pro-oxidant effects of high doses of ASC, with an average 50 % lethal concentration (LC50) of 3 mM, depending on cell type, ASC concentration, and time of exposure. Conversely, high doses of ASC neither did exert significant cytotoxic effects nor impaired the differentiation potential in cord blood (CB) CD34+ normal cells. Since plasma ASC concentrations within the millimolar (mM) range can be easily and safely reached by intravenous administration, we conclude that phase I/II clinical trials using high doses of ASC should be designed for patients with advanced/refractory AML and APL.

KW - Ascorbic acid

KW - Oxidative stress

KW - Reactive oxygen species

KW - Redox chemotherapy

KW - Sodium ascorbate

KW - Vitamin C

UR - http://www.scopus.com/inward/record.url?scp=84941997964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941997964&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2464-2

DO - 10.1007/s00277-015-2464-2

M3 - Article

VL - 94

SP - 1807

EP - 1816

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 11

ER -